Overactive Bladder
📧 Sign up to get email alerts when something new happens for Overactive Bladder.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-01-21Clinical Trial Update: The Role of Urinary ATP in the Diagnosis, Treatment, and Follow-up of Children With Overactive Bladder [NA]
A completed clinical trial from Marmara University investigated the role of urinary ATP as a biomarker for diagnosing, guiding treatment, an…
-
CLINICAL_TRIALS trial_result · 2025-01-20Clinical Trial Update: Exploratory Study of TAC-302 in Detrusor Underactivity Patients With Overactive Bladder. [Phase 2]
Phase 2 exploratory trial of TAC-302 in patients with detrusor underactivity and overactive bladder; results have been posted.
-
CLINICAL_TRIALS research · 2025-01-09Clinical Trial Update: Transcutaneous Tibial Nerve Stimulation Therapy in Children With Overactive Bladder [NA]
An ongoing pediatric clinical trial evaluating transcutaneous tibial nerve stimulation therapy for overactive bladder, currently enrolling b…
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: Efficacy of 200 IU OnabotulinumtoxinA in Idiopathic Overactive Bladder Resistant to Anticholinergic Treatment
A completed clinical trial evaluating the efficacy of 200 IU of onabotulinumtoxinA for idiopathic overactive bladder in patients who did not…
-
CLINICAL_TRIALS trial_result · 2024-12-27Clinical Trial Update: Composur: Study to Understand the Performance of Vibegron in Participants with Overactive Bladder (OAB)
A completed clinical trial evaluating the performance of vibegron in participants with overactive bladder. The study was sponsored by Urovan…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2024-12-18FDA Approved: GEMTESA — Supplemental Application (Sumitomo Pharma America, Inc.)
The FDA approved a supplemental application for GEMTESA (vibegron) submitted by Sumitomo Pharma America, Inc.
-
FDA approval · 2024-12-12FDA Approved: FESOTERODINE FUMARATE — Supplemental Application (Camber Pharmaceuticals, Inc.)
FDA approved a supplemental application for fesoterodine fumarate submitted by Camber Pharmaceuticals, Inc. under ANDA 204792. The action ap…
-
CLINICAL_TRIALS research · 2024-12-02Clinical Trial Update: Transcutaneous Medial Plantar Nerve Stimulation in Women With Idiopathic Overactive Bladder [NA]
A clinical trial update on transcutaneous medial plantar nerve stimulation for idiopathic overactive bladder in women; the study is currentl…
-
CLINICAL_TRIALS research · 2024-11-19Clinical Trial Update: Optimal Intravesical Lidocaine Volume for Pain Relief During Office Intra-detrusor Onabotulinum Toxin a Injections [Phase 4]
Phase 4 trial update evaluating the optimal intravesical lidocaine volume for pain relief during office intradetrusor injections of Onabotul…
-
CLINICAL_TRIALS trial_result · 2024-11-07Clinical Trial Update: Post Marketing Study to Evaluate the Efficacy and Safety of Solifenacin in Patients With OAB (Overactive Bladder) After TURP (Trans-urethral Resection of Prostate) or PVP (Photoselective Vaporization of Prostate) [Phase 4]
Phase 4 post-marketing study assessing the efficacy and safety of solifenacin for overactive bladder in patients after prostate surgery (TUR…
-
FDA approval · 2024-11-04FDA Approved: FESOTERODINE FUMARATE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application from Aurobindo Pharma Limited for fesoterodine fumarate, authorizing the marketing of a generic vers…
-
FDA approval · 2024-11-04FDA Approved: FESOTERODINE FUMARATE — Supplemental Application (Amneal Pharmaceuticals LLC)
The FDA approved a supplemental application for Amneal's fesoterodine fumarate, a generic version of the overactive bladder medication.
-
CLINICAL_TRIALS trial_result · 2024-10-31Clinical Trial Update: Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder [Phase 2]
A Phase 2 study evaluating the efficacy and safety of YM178 (mirabegron) for overactive bladder has completed.
-
CLINICAL_TRIALS trial_result · 2024-10-31Clinical Trial Update: A Study of YM178 in Patients With Symptomatic Overactive Bladder [Phase 2]
A Phase 2 study of YM178 for symptomatic overactive bladder conducted by Astellas has completed.
-
CLINICAL_TRIALS trial_result · 2024-10-31Clinical Trial Update: A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder [Phase 3]
A Phase 3 clinical trial evaluating YM178 for overactive bladder has completed, with safety and efficacy assessments conducted in patients.
-
CLINICAL_TRIALS trial_result · 2024-10-31Clinical Trial Update: A Study of YM178 in Subjects With Symptoms of Overactive Bladder [Phase 3]
Phase 3 trial of YM178 (mirabegron) for overactive bladder has completed.
-
CLINICAL_TRIALS trial_result · 2024-10-31Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB) [Phase 1]
This completed Phase 1 pediatric study assessed the pharmacokinetics, safety, and tolerability of Mirabegron oral suspension in children age…
-
CLINICAL_TRIALS research · 2024-10-31Clinical Trial Update: A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
A completed clinical trial evaluated how much anticholinergic burden is attributable to medications used for overactive bladder.
-
CLINICAL_TRIALS trial_result · 2024-10-31Clinical Trial Update: A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice
A prospective non-interventional study evaluated Betmiga (mirabegron) in routine clinical practice for overactive bladder and urinary incont…
-
CLINICAL_TRIALS research · 2024-10-30Clinical Trial Update: Diversity in Patients With OAB
A clinical trial update from University Hospital Ghent notes a NOT_YET_RECRUITING study exploring diversity in patients with overactive blad…
-
CLINICAL_TRIALS research · 2024-10-29Clinical Trial Update: Effect of Pelvic Floor Down-training on Women With Idiopathic Overactive Bladder [NA]
A clinical trial update evaluating whether pelvic floor down-training benefits women with idiopathic overactive bladder; the study is curren…
-
CLINICAL_TRIALS trial_result · 2024-10-22Clinical Trial Update: Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder [Phase 1]
Phase 1 single-dose pediatric trial to measure blood levels and safety of a drug for overactive bladder and neurogenic detrusor overactivity…
-
CLINICAL_TRIALS trial_result · 2024-10-22Clinical Trial Update: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder [Phase 1]
Phase 1 study assessing pharmacokinetics, safety and tolerability of Mirabegron OCAS in pediatric patients with Neurogenic Detrusor Overacti…
-
CLINICAL_TRIALS trial_result · 2024-10-22Clinical Trial Update: Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents [Phase 1]
This update details a Phase 1 pharmacokinetic study of solifenacin succinate suspension in children and adolescents with overactive bladder;…
-
CLINICAL_TRIALS research · 2024-10-16Clinical Trial Update: Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
A retrospective secondary data analysis assesses treatment persistence among patients with overactive bladder in Asia Oceania to understand …